Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Gosuranemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms TANGO
- Sponsors Biogen
- 24 Oct 2019 Planned End Date changed from 30 Jun 2024 to 26 Mar 2024.
- 24 Oct 2019 Planned primary completion date changed from 9 Jul 2021 to 25 May 2021.
- 13 Aug 2019 Status changed from recruiting to active, no longer recruiting.